Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
about
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisInterventions for guttate psoriasisParadoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overviewReview article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseInefficacy or paradoxical effect? Uveitis in ankylosing spondylitis treated with etanercept.Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients.New insights of T cells in the pathogenesis of psoriasisA study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.Alopecia secondary to anti-tumor necrosis factor-alpha therapyInhibition of 4-1BBL-regulated TLR response in macrophages ameliorates endotoxin-induced sepsis in mice.Genetic basis of TNF-α antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis.Familial secondary hyperhidrosis associated with tumor necrosis factor-alpha inhibitor treatment.Two Cases of Paradoxical Hidradenitis Suppurativa while on AdalimumabInfliximab-Associated Psoriasiform Dermatitis: Case Report and Review of a Seemingly Paradoxical Inflammatory Response.Psoriasiform Eruption and Worsening of Pustulosis Palmoplantaris After Treatment with Two Anti-TNF-α Inhibitors, Followed by Successful Treatment with Ustekinumab.Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn's Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies.Management of palmoplantar pustulosis: do we need to change?Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature.Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.Paradoxical effects of anti-TNF-α agents in inflammatory diseases.Adverse reactions to biologic agents and their medical management.Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease.Biologic response modifiers and pediatric psoriasis.Palmoplantar pustular psoriasis induced by adalimumab: a case report and literature review.Etanercept for treating axial spondyloarthritis.Etanercept for the treatment of non-radiographic axial spondyloarthritis.The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.What do we know about palmoplantar pustulosis?New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases.Paradoxical Side Effect Related With Anti-Tumor Necrosis Factor Alpha Treatment.[Pustular psoriasis].Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.Biologics in dermatology: adverse effects.[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.
P2860
Q22305863-64662B1F-8CDB-4E3A-96EE-0473454AA262Q24188296-8E8B6A8F-20A6-442A-B071-CA25545E1AF0Q26738918-B9B0CBD1-54DD-4ECB-8717-400F31B7728CQ26822029-6F11CE27-6E6F-49B6-9D7A-9DDAA321B53CQ33786723-DBCB896A-A492-457E-8DBA-C8C53AED1D40Q33829739-AFBF0960-469B-4843-9C28-8083CFCC7FB3Q34043846-4D2593E9-0D69-46E0-BBD5-1B022D610AE3Q35100143-3F5E01E9-4922-48F5-AD52-B35E971B47ECQ35211826-9E59CF25-C402-4FE9-8964-10C2508D392FQ35565652-A33E6B93-EE4B-448D-B692-24EC81FE8DE4Q36586054-85B481EA-6F08-4887-8142-BF07D1AF6B6FQ36733728-61F70581-CD8B-47F4-A86E-54207ABE57CDQ37057086-E43A1A6F-43DB-468F-8351-E638A72D837CQ37329074-C184DA44-EE34-4F2A-AAFD-D954B672D382Q37432268-AD045AF4-64F0-4CE0-8CD0-16B49D5C7E2EQ37432287-D78CD8E6-FC13-4190-98B2-569123D9E16BQ37833129-DF67C064-6FF7-4018-9E7E-D4DC548CE63EQ37873493-000935A3-2E9A-4AF1-9A47-01B4718D2A2DQ37980484-26998CD8-A373-49C4-AE74-1374EB37A56FQ38024281-5A7F8D70-B302-40B6-8B68-A4AF08833581Q38034394-1E58F62F-EB32-4155-9806-DE922DA14C6FQ38049779-5A80630E-8DD0-4C6C-BF71-51A2AF98FB28Q38050938-E48EE497-5CF0-44E6-AFF8-676D76E24EE7Q38145501-4D810B69-F175-46AA-88EA-A048B0A24456Q38170158-2E5B00A0-03F2-4B92-AAE0-69AA52698C04Q38238948-E077CD11-0FA7-4146-A374-335D3BCD12E7Q38315640-F57F0EFF-81FE-413B-A7E1-7A48D83A9399Q38366432-0573DE74-427C-4E04-B367-A8DC8F927BEAQ38562060-EA52FFAE-0216-464B-826F-D95CB66FF305Q38691419-E5A49C68-7349-4EA2-B292-920593AC8EFFQ38703849-F736BF44-6E48-4526-8313-F9612E2318FBQ38755133-0268FD69-EB95-407E-9D5E-26E309E7032CQ38926801-EB478C7F-2AAF-4F52-85D7-A9FD06D712C1Q39690095-2F9CAF97-8F59-4D57-BCAA-8E65F3C0EB66Q40101338-F890DB78-9767-4816-99AE-D6F1FDD16D8CQ40653524-3AD1F74F-D6E8-4399-89EC-8EB0474484E9Q40792685-2E7608AB-0BAF-4F9B-AD43-0DBB7BFF272FQ41120913-83F71CE8-AFC7-4137-8B16-D9AB4446E261Q41176187-DBEDACFC-C82F-4760-83C3-B637BE988F8CQ41520678-00A5AE31-D230-4ECA-8E46-236D83595558
P2860
Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Psoriatic skin lesions induced ...... d possible immunopathogenesis.
@en
Psoriatic skin lesions induced ...... d possible immunopathogenesis.
@nl
type
label
Psoriatic skin lesions induced ...... d possible immunopathogenesis.
@en
Psoriatic skin lesions induced ...... d possible immunopathogenesis.
@nl
prefLabel
Psoriatic skin lesions induced ...... d possible immunopathogenesis.
@en
Psoriatic skin lesions induced ...... d possible immunopathogenesis.
@nl
P1476
Psoriatic skin lesions induced ...... d possible immunopathogenesis.
@en
P2093
Angelique N Collamer
Daniel F Battafarano
P304
P356
10.1016/J.SEMARTHRIT.2010.04.003
P577
2010-06-26T00:00:00Z